X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs PLETHICO PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA PLETHICO PHARMA SANOFI INDIA/
PLETHICO PHARMA
 
P/E (TTM) x 39.5 -1.1 - View Chart
P/BV x 8.5 0.0 50,868.8% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 SANOFI INDIA   PLETHICO PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
PLETHICO PHARMA
Mar-14
SANOFI INDIA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560395 1,154.7%   
Low Rs4,40031 14,057.5%   
Sales per share (Unadj.) Rs1,028.5604.4 170.2%  
Earnings per share (Unadj.) Rs129.032.5 397.1%  
Cash flow per share (Unadj.) Rs186.051.3 362.3%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.6473.6 159.1%  
Shares outstanding (eoy) m23.0334.08 67.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.40.4 1,235.4%   
Avg P/E ratio x34.76.6 529.5%  
P/CF ratio (eoy) x24.14.2 580.2%  
Price / Book Value ratio x5.90.5 1,321.0%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1747,262 1,420.7%   
No. of employees `0003.6NA-   
Total wages/salary Rs m3,5921,596 225.1%   
Avg. sales/employee Rs Th6,537.7NM-  
Avg. wages/employee Rs Th991.4NM-  
Avg. net profit/employee Rs Th819.8NM-  
INCOME DATA
Net Sales Rs m23,68620,598 115.0%  
Other income Rs m708386 183.3%   
Total revenues Rs m24,39420,984 116.2%   
Gross profit Rs m5,2812,818 187.4%  
Depreciation Rs m1,313642 204.4%   
Interest Rs m151,593 0.9%   
Profit before tax Rs m4,661969 481.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691-138 -1,222.0%   
Profit after tax Rs m2,9701,107 268.3%  
Gross profit margin %22.313.7 163.0%  
Effective tax rate %36.3-14.3 -253.9%   
Net profit margin %12.55.4 233.3%  
BALANCE SHEET DATA
Current assets Rs m15,67318,877 83.0%   
Current liabilities Rs m6,67811,896 56.1%   
Net working cap to sales %38.033.9 112.1%  
Current ratio x2.31.6 147.9%  
Inventory Days Days7636 211.5%  
Debtors Days Days22198 11.3%  
Net fixed assets Rs m8,0989,861 82.1%   
Share capital Rs m230341 67.6%   
"Free" reserves Rs m17,08812,331 138.6%   
Net worth Rs m17,35616,139 107.5%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m25,40033,146 76.6%  
Interest coverage x311.71.6 19,387.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.6 150.1%   
Return on assets %11.88.1 144.3%  
Return on equity %17.16.9 249.5%  
Return on capital %26.912.3 219.2%  
Exports to sales %24.521.4 114.6%   
Imports to sales %28.015.2 183.8%   
Exports (fob) Rs m5,8014,402 131.8%   
Imports (cif) Rs m6,6273,136 211.3%   
Fx inflow Rs m7,1454,402 162.3%   
Fx outflow Rs m6,8463,184 215.0%   
Net fx Rs m2991,219 24.5%   
CASH FLOW
From Operations Rs m3,2262,437 132.4%  
From Investments Rs m-1,555-6,265 24.8%  
From Financial Activity Rs m-1,8182,490 -73.0%  
Net Cashflow Rs m-147-1,337 11.0%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 4.3 334.9%  
FIIs % 14.6 5.5 265.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 7.5 140.0%  
Shareholders   15,184 10,665 142.4%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 18, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - UNICHEM LAB COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS